Organon & Co. (NYSE:OGN) Announces Quarterly Earnings Results

Organon & Co. (NYSE:OGN) released its earnings results on Thursday. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09), Zacks reports. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Stock Down 3.0 %

Shares of OGN stock traded down $0.48 during trading on Friday, hitting $15.84. 677,597 shares of the company were exchanged, compared to its average volume of 2,697,114. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of 3.14, a P/E/G ratio of 0.83 and a beta of 0.76. The business’s 50-day simple moving average is $15.34 and its 200 day simple moving average is $17.53. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10.

Analyst Ratings Changes

Several equities analysts have recently weighed in on OGN shares. Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley reduced their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.